Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - pembrolizumab -

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pembrolizumab - infusion, solution concentrate - pembrolizumab 25.0 mg/ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

msd (pty) ltd - infusion (parenteral) - see ingredients - each 1,0 ml solution contains pembrolizumab 25,0 mg

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastic agents - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment

Canada - English - Health Canada

loxo oncology inc - selpercatinib - capsule - 40mg - selpercatinib 40mg - antineoplastic agents

Canada - English - Health Canada

loxo oncology inc - selpercatinib - capsule - 80mg - selpercatinib 80mg - antineoplastic agents